Patient Education · ADHD Medication
ADHD medication safety: what to expect, what to watch, and what to report
Families usually arrive with two contradictory sets of information: that ADHD medication is harmless, and that it is dangerous and addictive. Neither is accurate. The medicines have a reasonably well-mapped side-effect profile, a small and measurable effect on the heart, a real but frequently misunderstood relationship with substance use, and a monitoring schedule that exists precisely because these things can be tracked.
The First Few Weeks
Most early effects are
predictable and manageable
With stimulants, the commonest early effects are reduced appetite, difficulty falling asleep, headache, dry mouth, and a period of irritability or flatness as a dose wears off, sometimes described as a rebound. Some people notice a faster heartbeat or feel slightly wired. Most of these are dose-related and timing-related rather than permanent.
Your prescriber can often settle these without abandoning treatment, by changing when the dose is taken, adding a substantial breakfast before it and a later evening meal, moving the last dose earlier, or changing formulation. Do not alter the dose, timing or formulation of methylphenidate yourself; it is a controlled medicine and those changes belong with the prescriber. Atomoxetine has a different pattern: nausea and appetite change early on, sometimes tiredness, and a slower build to any benefit.
A useful rule during titration is to judge the medicine on function rather than on sensation. Feeling nothing dramatic is not failure, and feeling intensely focused on day one is not proof of the right dose.
What to Report
Some effects need
attention straight away
Atomoxetine carries a boxed warning in its United States prescribing information about suicidal thoughts in children and adolescents, based on pooled short-term trials in which suicidal ideation occurred in about 0.4 per cent of those taking atomoxetine and in none of those taking placebo. No suicides occurred in those trials. The same warning appears in United Kingdom and European labelling in a different format. Severe liver injury is separately described as rare but real, which is why jaundice or unexplained abdominal symptoms should stop the medicine and prompt review.
Heart and Blood Pressure
A small average rise,
which is why it is measured
A 2025 network meta-analysis of 102 randomised trials, covering more than 13,000 children and adolescents and more than 9,000 adults, found that amphetamines, atomoxetine, lisdexamfetamine, methylphenidate and viloxazine all produced small increases in blood pressure, heart rate or both. In children and adolescents the average rise in systolic blood pressure was roughly one to two millimetres of mercury, and pulse rose by roughly three to six beats per minute. Guanfacine moved in the opposite direction, lowering both.
These are group averages, not individual predictions, and they are the reason pulse and blood pressure are checked before and after each dose change and at least every six months. The authors made the point that monitoring should apply to any ADHD medication and not only to stimulants. Whether many years of cumulative use affects the risk of cardiovascular disease has been examined in large national datasets and remains debated; the practical response in the clinic is the same either way, which is to measure rather than to assume.
Existing hypertension, a personal or family cardiac history, or another medicine that affects the heart do not automatically rule out treatment, but they change the assessment and sometimes prompt cardiology review before starting.
Growth in Children
Height is tracked
for a reason
A 2024 systematic review and meta-analysis of 29 studies found a small to moderate average reduction in height with methylphenidate, a standardised mean difference of −0.40 (95 per cent confidence interval −0.54 to −0.27), with very high variation between studies. The size of the effect for any individual child is uncertain, and the studies are not consistent enough to translate into a reliable figure in centimetres.
This is precisely why NICE asks for height every six months in children and young people, plotted on a growth chart and reviewed by the clinician responsible for treatment, alongside weight at defined intervals. If height falls behind what is expected, a planned break over school holidays may be considered to allow catch-up growth. If weight is the concern, options include taking the medicine with food, adding meals or snacks, changing dose timing, a planned break, or switching medicine.
Routine drug holidays for their own sake are not recommended. Breaks are a response to a specific problem, or a deliberate trial to test whether medication is still needed.
The Addiction Question
Treatment risk and misuse risk
are two different questions
This is among the questions Indian families ask most often, and it deserves a careful answer rather than blanket reassurance. A 2013 meta-analysis of fifteen longitudinal studies concluded that treating ADHD with stimulant medication neither protected against nor increased the risk of later substance use disorders. A large 2017 within-individual cohort study of around three million patients found that periods on medication were associated with fewer substance-related events, with the association weakening over a two-year lag.
The summary is that prescribed, monitored stimulant treatment does not appear to create addiction, and some large real-world studies found fewer substance-related problems during the periods when people were actually taking it. It would overstate the evidence to promise a long-term protective effect.
Misuse and diversion are a separate question from whether prescribed treatment causes addiction. A meta-analysis of college students estimated stimulant misuse at around 17 per cent, with peers who hold prescriptions the commonest source. Much non-medical use involves people without a diagnosis, but people with ADHD are not exempt, particularly alongside substance use, and the risk is better discussed openly than assumed absent. Reliable Indian data are lacking, and Western student figures should not be assumed to describe Indian students. What follows practically is simple: the medicine belongs to the person it was prescribed for, it should be stored securely, and it should never be shared.
Sexual Side Effects
Under-asked,
and under-researched
Changes in libido, arousal, erectile function or ejaculation are occasionally reported with both stimulants and atomoxetine. The evidence base here is thin, resting largely on case reports and post-marketing surveillance rather than on good comparative trials, so confident claims that one medicine is clearly worse than another go beyond what the data support.
Two clinical points are more reliable than the rankings circulating online. First, ADHD and its common companions, including depression, anxiety, relationship strain and alcohol use, affect sexual function independently of any medicine, so a baseline matters before attributing a change to treatment. Second, this is a common reason people quietly stop taking medication without telling anyone, which is the least useful of the available outcomes, because nothing can then be adjusted. Priapism is rare but is a medical emergency and needs immediate attention.
If something has changed, say so. Dose, timing, formulation and choice of medicine can all be revisited. The sexual health page covers assessment of these difficulties more broadly.
Stopping and Reviewing
Continuing should be
a decision, not a default
ADHD medication should be reviewed at least once a year, covering whether it is still helping, whether adverse effects have emerged, whether doses are being missed, and whether the person still wants to take it. Trial periods of reducing or stopping are a legitimate part of that review.
Stimulants do not cause a physical withdrawal syndrome in the way that benzodiazepines do, but stopping abruptly can bring symptoms back quickly, sometimes with a few days of tiredness or low mood, which is easy to misread as depression. Atomoxetine, similarly, is not habit-forming, but its benefit fades over weeks rather than immediately. Planned reduction, with a clear plan for what to watch, is more informative than an unplanned stop.
For medicines that do produce a withdrawal syndrome, a separate article on dependence and psychiatric medication explains the distinction in more depth.
Care With Dr. Shaurya Garg
If this article
sounds familiar
What is actually available in India, and the rules governing stimulant prescriptions, are covered in ADHD medication in India. For how medication fits alongside everything else, see building a treatment plan after diagnosis.
Dr Shaurya Garg provides structured ADHD assessment and treatment online across India and in person in New Delhi.
Sources & Further Reading
· NICE NG87: attention deficit hyperactivity disorder, diagnosis and management
· Farhat and colleagues, comparative cardiovascular safety of ADHD medication, Lancet Psychiatry, 2025
Sources are provided for education and were reviewed on 28 July 2026. They do not replace individual clinical assessment.
Common Questions
Safety questions,
answered from the evidence
Do ADHD stimulants cause addiction when taken as prescribed?
The available evidence does not show that prescribed, monitored stimulant treatment causes addiction. A meta-analysis found neither increased nor decreased risk of later substance use disorders, and a large cohort study found fewer substance-related events during medicated periods. Misuse by people without a prescription is a separate problem.
Will ADHD medication damage my heart?
Trials show small average increases in blood pressure and heart rate with most ADHD medicines. That is why pulse and blood pressure are measured before and after every dose change and at least every six months, and why a cardiovascular assessment is done before starting. Specific cardiac history may warrant cardiology review first.
Will medication stop my child growing?
A 2024 meta-analysis of 29 studies found a small to moderate average reduction in height with methylphenidate, a standardised mean difference of −0.40, with very high variation between studies. Height is therefore measured every six months and plotted on a growth chart, and a planned break over school holidays may be considered if growth falls behind.
Is it safe to take a break from ADHD medication?
Routine drug holidays are not recommended for their own sake. Planned breaks are used for a specific reason, such as concern about growth or weight, or as a deliberate trial at annual review to see whether medication is still needed. Discuss it rather than stopping on your own.
My appetite has disappeared. Should I stop the medicine?
Speak to your prescriber first. Reduced appetite is common early on and often responds to eating before the dose, adding a later meal, changing the timing or adjusting the dose. Persistent weight loss does need review.